- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: AZ 12012199 | AZ-12012199 | AZ12012199 | AZD 6703 | AZD-6703
Compound class: Synthetic organic
Comment: AZD6703 is a potent, selective and reversible orally bioavailable inhibitor of p38 mitogen-activated protein kinase 14 (MAPK14).
This compound was in the AstraZeneca/MRC repurposing list from 2011.
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
|No information available.|
|Summary of Clinical Use|
|AZD6703 was investigated as a potential treatment for inflammatory diseases such as osteoarthritis.|
|Mechanism Of Action and Pharmacodynamic Effects|
|AZD6703 is an inhibitor of p38a MAP kinase (MAPK14). p38α mitogen-activated protein kinase (MAPK) is critical for the regulation of pro-inflammatory cytokines such as tumour necrosis factor alpha (TNF-α) and interleukin-1β (IL-1β). Over production of these cytokines is linked to the inflammatory processes driving a broad range of diseases including rheumatoid arthritis, psoriasis, inflammatory bowel disease, multiple sclerosis, ischaemia , Alzheimer's disease, and neuropathic pain [3-4].|